GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » AVEO Pharmaceuticals Inc (STU:VPA1) » Definitions » Cyclically Adjusted PB Ratio

AVEO Pharmaceuticals (STU:VPA1) Cyclically Adjusted PB Ratio : (As of Jun. 07, 2024)


View and export this data going back to 2013. Start your Free Trial

What is AVEO Pharmaceuticals Cyclically Adjusted PB Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


AVEO Pharmaceuticals Cyclically Adjusted PB Ratio Historical Data

The historical data trend for AVEO Pharmaceuticals's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

AVEO Pharmaceuticals Cyclically Adjusted PB Ratio Chart

AVEO Pharmaceuticals Annual Data
Trend Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

AVEO Pharmaceuticals Quarterly Data
Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of AVEO Pharmaceuticals's Cyclically Adjusted PB Ratio

For the Biotechnology subindustry, AVEO Pharmaceuticals's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


AVEO Pharmaceuticals's Cyclically Adjusted PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, AVEO Pharmaceuticals's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where AVEO Pharmaceuticals's Cyclically Adjusted PB Ratio falls into.



AVEO Pharmaceuticals Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

AVEO Pharmaceuticals's Cyclically Adjusted Book per Share for the quarter that ended in Sep. 2022 is calculated as:

For example, AVEO Pharmaceuticals's adjusted Book Value per Share data for the three months ended in Sep. 2022 was:

Adj_Book=Book Value per Share/CPI of Sep. 2022 (Change)*Current CPI (Sep. 2022)
=0.841/125.2265*125.2265
=0.841

Current CPI (Sep. 2022) = 125.2265.

AVEO Pharmaceuticals Quarterly Data

Book Value per Share CPI Adj_Book
201212 20.701 96.871 26.760
201303 21.022 98.209 26.805
201306 15.809 98.518 20.095
201309 12.292 98.790 15.581
201312 9.854 98.326 12.550
201403 8.891 99.695 11.168
201406 6.608 100.560 8.229
201409 5.090 100.428 6.347
201412 3.196 99.070 4.040
201503 2.451 99.621 3.081
201506 1.797 100.684 2.235
201509 3.657 100.392 4.562
201512 2.718 99.792 3.411
201603 1.530 100.470 1.907
201606 0.973 101.688 1.198
201609 0.415 101.861 0.510
201612 -0.240 101.863 -0.295
201703 0.416 102.862 0.506
201706 -1.473 103.349 -1.785
201709 -3.161 104.136 -3.801
201712 -2.911 104.011 -3.505
201803 -3.428 105.290 -4.077
201806 -3.269 106.317 -3.850
201809 -4.258 106.507 -5.006
201812 -1.892 105.998 -2.235
201903 -1.183 107.251 -1.381
201906 0.090 108.070 0.104
201909 1.060 108.329 1.225
201912 0.831 108.420 0.960
202003 0.394 108.902 0.453
202006 1.653 108.767 1.903
202009 1.323 109.815 1.509
202012 1.079 109.897 1.230
202103 1.771 111.754 1.984
202106 1.454 114.631 1.588
202109 1.267 115.734 1.371
202112 1.178 117.630 1.254
202203 0.973 121.301 1.004
202206 0.836 125.017 0.837
202209 0.841 125.227 0.841

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


AVEO Pharmaceuticals  (STU:VPA1) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


AVEO Pharmaceuticals Cyclically Adjusted PB Ratio Related Terms

Thank you for viewing the detailed overview of AVEO Pharmaceuticals's Cyclically Adjusted PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


AVEO Pharmaceuticals (STU:VPA1) Business Description

Traded in Other Exchanges
N/A
Address
30 Winter Street, Boston, MA, USA, 02108
AVEO Pharmaceuticals Inc is a commercial-stage, oncology-focused biopharmaceutical company engaged in offering medicines that provide a better life for patients with cancer. The company markets FOTIVDA (tivozanib) in the United States. FOTIVDA is an oral, next-generation vascular endothelial growth factor receptor, or VEGFR, tyrosine kinase inhibitor, or TKI. The group primarily operates in the U.S.

AVEO Pharmaceuticals (STU:VPA1) Headlines

No Headlines